AstraZeneca is a global patient-oriented biopharmaceutical company focused on the research, development, and expansion of access to medications primarily in therapeutic areas such as oncology, cardiology, nephrology, metabolic disorders, respiratory and autoimmune diseases, as well as rare diseases. For over 100 years, AstraZeneca has been developing and producing innovative pharmaceutical products that expand the possibilities of modern medicine and improve patients’ lives. AstraZeneca is among the top 5 international biopharmaceutical companies engaged in research and production of prescription medicines in more than 100 countries. Millions of patients worldwide use innovative products manufactured by AstraZeneca.

AstraZeneca's representative office in Kazakhstan was opened in 2007. Currently, the company employs over 200 people across more than 19 cities in the country, including Almaty, Astana, Karaganda, Shymkent, Aktobe, Ust-Kamenogorsk, Uralsk, and others. In 2024 and 2025, the company was recognized as the best employer by the Top Employer Institute. Currently, there are about 30 AstraZeneca products registered in Kazakhstan in therapeutic areas such as oncology, respiratory and autoimmune diseases, cardiovascular diseases, and metabolic disorders.

In September 2023, a Limited Liability Partnership "AstraZeneca Kazakhstan" was registered in Kazakhstan, marking the beginning of a new stage of the company's development in the Republic. The registration of a local legal entity with its own warehouse will allow AstraZeneca to increase its business presence in Kazakhstan, become a more attractive partner for distributors and government bodies, and expand access to innovative therapy for millions of patients in Kazakhstan.